| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8442146 | European Journal of Cancer | 2015 | 9 Pages |
Abstract
Doxorubicin continues to be the standard treatment in eligible patients with advanced/metastatic soft-tissue sarcoma (STS). Trabectedin 1.5Â mg/m2/24-hour infusion is the overall proven approach to delivering this agent in the second-line setting for patients with advanced or metastatic STS.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
B. Bui-Nguyen, J.E. Butrynski, N. Penel, J.Y. Blay, N. Isambert, M. Milhem, J.M. Kerst, A.K.L Reyners, S. Litière, S. Marréaud, F. Collin, W.T.A van der Graaf,